Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Synthesis of Scandium Phosphate after Peroxide Assisted Leaching of Iron Depleted Bauxite Residue (Red Mud) Slags.

Yagmurlu B, Alkan G, Xakalashe B, Schier C, Gronen L, Koiwa I, Dittrich C, Friedrich B.

Sci Rep. 2019 Aug 14;9(1):11803. doi: 10.1038/s41598-019-48390-z.

2.

A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.

Goel S, Swami U, Kumar K, Dittrich C, Reyderman L, Jain M, Aisner J, Song J, Petrylak DP.

Cancer Chemother Pharmacol. 2019 Sep;84(3):567-578. doi: 10.1007/s00280-019-03877-4. Epub 2019 Jun 12.

PMID:
31190276
3.

Matriline effects on metamorphic traits in a natural system in the European common frog (Rana temporaria).

Dittrich C, Huster J, Rödel MO, Feldhaar H.

Ecol Evol. 2019 Feb 21;9(6):3075-3088. doi: 10.1002/ece3.4811. eCollection 2019 Mar.

4.

Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial.

Dittrich C, Königsberg R, Mittlböck M, Geissler K, Sahmanovic-Hrgovcic A, Pleiner-Duxneuner J, Czejka M, Buchner P.

Invest New Drugs. 2019 Feb;37(1):127-138. doi: 10.1007/s10637-018-0639-0. Epub 2018 Jul 12.

PMID:
29998365
5.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF.

Cancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30.

6.

Temporal migration patterns and mating tactics influence size-assortative mating in Rana temporaria.

Dittrich C, Rodríguez A, Segev O, Drakulić S, Feldhaar H, Vences M, Rödel MO.

Behav Ecol. 2018 Mar-Apr;29(2):418-428. doi: 10.1093/beheco/arx188. Epub 2018 Jan 10.

7.

Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.

Gruber A, Czejka M, Buchner P, Kitzmueller M, Kirchbaumer Baroian N, Dittrich C, Sahmanovic Hrgovcic A.

Cancer Chemother Pharmacol. 2018 Apr;81(4):763-771. doi: 10.1007/s00280-018-3545-4. Epub 2018 Feb 16.

8.

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.

Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I.

JAMA Oncol. 2018 Mar 1;4(3):302-308. doi: 10.1001/jamaoncol.2017.4612.

9.

Stable isotope analyses-A method to distinguish intensively farmed from wild frogs.

Dittrich C, Struck U, Rödel MO.

Ecol Evol. 2017 Mar 14;7(8):2525-2534. doi: 10.1002/ece3.2878. eCollection 2017 Apr.

10.

Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology.

Dittrich C, Kosty MP, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir NS, Lotz JP, Österlund P, Pavlidis N, Purkalne G.

J Clin Oncol. 2017 Jan 10;35(2):254-255. Epub 2016 Oct 31. Review. No abstract available.

PMID:
28056204
11.

Reply to the letter to the editor 'Integrating communication as a core skill in the global curriculum for medical oncology' by Horlait et al.

Dittrich C, Stiefel F, Kiss A, Dizon DS.

Ann Oncol. 2017 Apr 1;28(4):905-906. doi: 10.1093/annonc/mdw679. No abstract available.

PMID:
28049138
12.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

13.

The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe.

Pavlidis N, Alba E, Berardi R, Bergh J, El Saghir N, Jassem J, Kosty M, Lopez RI, Lotz JP, Österlund P, Purkalne G, Dittrich C.

ESMO Open. 2016 Jan 18;1(1):e000004. eCollection 2016. No abstract available.

14.

Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients.

Rachar V, Czejka M, Kitzmueller M, Buchner P, Lichtneckert M, Greil R, Geiler H, Dittrich C.

Anticancer Res. 2016 Sep;36(9):4715-23.

PMID:
27630318
15.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO Global Curriculum Working Group.

Ann Oncol. 2016 Aug;27(8):1378-81. doi: 10.1093/annonc/mdw239. No abstract available.

16.

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.

Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H, Dittrich C, Messina C, Beauvois M, Trapp E, Goulioti T, Tryfonidis K, Pantel K, Repollet M, Janni W, Piccart M, Sotiriou C, Litiere S, Pierga JY.

Eur J Cancer. 2016 Aug;63:97-104. doi: 10.1016/j.ejca.2016.04.024. Epub 2016 Jun 10. Review.

PMID:
27289552
17.

Breast Cancer Subtypes in Patients Aged 70 Years and Older.

Königsberg R, Pfeiler G, Hammerschmid N, Holub O, Glössmann K, Larcher-Senn J, Dittrich C.

Cancer Invest. 2016 May 27;34(5):197-204. doi: 10.1080/07357907.2016.1182184. Epub 2016 May 23. Review.

PMID:
27215407
18.

Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors.

Borlak J, Länger F, Spanel R, Schöndorfer G, Dittrich C.

Oncotarget. 2016 May 10;7(19):28059-74. doi: 10.18632/oncotarget.8574.

19.

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, Greil R; AGMT-NHL13 Investigators.

Haematologica. 2015 Jul;100(7):955-63. doi: 10.3324/haematol.2015.125344. Epub 2015 Apr 24.

20.

The changing world of drug development.

Dittrich C.

Chin Clin Oncol. 2014 Jun;3(2):12. doi: 10.3978/j.issn.2304-3865.2014.05.12.

21.

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.

Mau-Sørensen M, Dittrich C, Dienstmann R, Lassen U, Büchler W, Martinius H, Tabernero J.

Cancer Chemother Pharmacol. 2015 May;75(5):1065-73. doi: 10.1007/s00280-015-2728-5. Epub 2015 Mar 27.

PMID:
25814216
22.

An ESMO-EORTC position paper on the EU clinical trials regulation and EMA's transparency policy: making European research more competitive again.

Dittrich C, Negrouk A, Casali PG; European Society for Medical Oncology (ESMO) Switzerland, and the European Organisation for Research and Treatment of Cancer (EORTC), Belgium.

Ann Oncol. 2015 May;26(5):829-32. doi: 10.1093/annonc/mdv154. Epub 2015 Mar 23. No abstract available.

PMID:
25802239
23.

A simple method for comparing enzymatic capecitabine activation in various mono- and combination chemotherapies.

Buchner P, Sahmanovic A, Schreiber V, Baroian N, Dittrich C, Czejka M.

Pharmacology. 2015;95(1-2):29-31. doi: 10.1159/000369934. Epub 2015 Jan 9.

PMID:
25591914
24.

Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.

Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, Weltermann A, Thaler J, Hufnagl C, Gampenrieder SP, Rinnerthaler G, Ressler S, Ulmer H, Greil R.

Anticancer Res. 2015 Jan;35(1):517-21.

PMID:
25550597
25.

A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors.

Dittrich C, Fridrik MA, Koenigsberg R, Lee C, Goeldner RG, Hilbert J, Greil R.

Invest New Drugs. 2015 Apr;33(2):409-22. doi: 10.1007/s10637-014-0201-7. Epub 2014 Dec 23.

26.

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.

Milowsky MI, Dittrich C, Durán I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn DI, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN.

Eur J Cancer. 2014 Dec;50(18):3145-52. doi: 10.1016/j.ejca.2014.10.013. Epub 2014 Oct 30.

PMID:
25457633
27.

Quantitative profiling of peptides from RNAs classified as noncoding.

Prabakaran S, Hemberg M, Chauhan R, Winter D, Tweedie-Cullen RY, Dittrich C, Hong E, Gunawardena J, Steen H, Kreiman G, Steen JA.

Nat Commun. 2014 Nov 18;5:5429. doi: 10.1038/ncomms6429.

28.

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab.

Königsberg R, Maierhofer J, Steininger T, Kienzer G, Dittrich C.

Radiol Oncol. 2014 Apr 25;48(2):184-8. doi: 10.2478/raon-2013-0083. eCollection 2014 Jun.

29.

Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.

Schreiber V, Kitzmueller M, Poxhofer M, Gintersdorfer S, Neudorfer C, Lichtneckert M, Dittrich C, Czejka M.

Anticancer Res. 2014 Jul;34(7):3371-6.

PMID:
24982342
30.

Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.

De Santis M, Bachner M, Cerveny M, Kametriser G, Steininger T, Königsberg R, Schratter-Sehn A, Sedlmayer F, Dittrich C.

Ann Oncol. 2014 Sep;25(9):1789-94. doi: 10.1093/annonc/mdu209. Epub 2014 Jun 16.

PMID:
24936582
31.

A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.

Dittrich C, Papai-Szekely Z, Vinolas N, Sederholm C, Hartmann JT, Behringer D, Kazeem G, Desaiah D, Leschinger MI, von Pawel J.

Eur J Cancer. 2014 Jun;50(9):1571-80. doi: 10.1016/j.ejca.2014.03.007. Epub 2014 Apr 2.

PMID:
24703574
32.

Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels.

Czejka M, Sahmanovic A, Buchner P, Steininger T, Dittrich C.

Case Rep Oncol. 2013 Dec 12;6(3):602-8. doi: 10.1159/000357211. eCollection 2013 Sep.

33.

Nicotine affects pancreatic cell proteomics across species.

Dittrich C.

Proteomics. 2013 May;13(9):1379-80. doi: 10.1002/pmic.201300092.

PMID:
23606677
34.
35.

How transferable are recommendations of the era of treating conventionally defined breast cancer for the era of molecularly characterised breast cancer?

Königsberg R, Dittrich C.

Gland Surg. 2012 Nov;1(3):156-8. doi: 10.3978/j.issn.2227-684X.2012.10.02. No abstract available.

36.

Acute Reversible Heart Failure Caused by Coronary Vasoconstriction due to Continuous 5-Fluorouracil Combination Chemotherapy.

Dechant C, Baur M, Böck R, Czejka M, Podczeck-Schweighofer A, Dittrich C, Christ G.

Case Rep Oncol. 2012 May;5(2):296-301. doi: 10.1159/000339573. Epub 2012 Jun 5.

37.

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.

Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, Hollerbach S, Merger M, Munzert G, Fleischer F, Scheulen ME.

Br J Cancer. 2012 Jul 10;107(2):280-6. doi: 10.1038/bjc.2012.257. Epub 2012 Jun 14.

38.

Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients.

Königsberg R, Pfeiler G, Klement T, Hammerschmid N, Brunner A, Zeillinger R, Singer C, Dittrich C.

Eur J Cancer. 2012 Nov;48(16):2962-8. doi: 10.1016/j.ejca.2012.04.019. Epub 2012 May 28.

PMID:
22647688
39.

A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer.

Dittrich C, Solska E, Manikhas A, Eniu A, Tjulandin S, Anghel R, Musib L, Frimodt-Moller B, Liu Y, Krejcy K, Láng I.

Cancer Invest. 2012 May;30(4):309-16. doi: 10.3109/07357907.2012.657812. Epub 2012 Apr 2.

PMID:
22468806
40.

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.

Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, Campone MM, Twelves CC, Raymond E, Hegi ME, Lacombe D, van den Bent MJ.

Eur J Cancer. 2012 May;48(8):1176-84. doi: 10.1016/j.ejca.2012.02.004. Epub 2012 Mar 28.

PMID:
22464345
41.

LEM-3 - A LEM domain containing nuclease involved in the DNA damage response in C. elegans.

Dittrich CM, Kratz K, Sendoel A, Gruenbaum Y, Jiricny J, Hengartner MO.

PLoS One. 2012;7(2):e24555. doi: 10.1371/journal.pone.0024555. Epub 2012 Feb 23.

42.

Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients.

Königsberg R, Hulla W, Klimpfinger M, Reiner-Concin A, Steininger T, Büchler W, Terkola R, Dittrich C.

Oncology. 2011;81(5-6):359-64. doi: 10.1159/000334919. Epub 2012 Jan 13.

PMID:
22248908
43.

General oncology and neurological complications.

Steiger D, Dittrich C.

Handb Clin Neurol. 2012;105:677-81. doi: 10.1016/B978-0-444-53502-3.00017-3. Review. No abstract available.

PMID:
22230527
44.

Delivery of membrane impermeable cargo into CHO cells by peptide nanoparticles targeted by a protein corona.

Dittrich C, Burckhardt CJ, Danuser G.

Biomaterials. 2012 Mar;33(9):2746-53. doi: 10.1016/j.biomaterials.2011.12.016. Epub 2012 Jan 9.

45.

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).

Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, Ciruelos E, Pavesi L, Semiglazov V, De Benedictis E, Gaion F, Bari M, Morandi P, Valagussa P, Luca G.

Breast Cancer Res Treat. 2012 Apr;132(3):843-51. doi: 10.1007/s10549-011-1660-6. Epub 2011 Jul 13.

PMID:
21750964
46.

2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.

Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, Gillessen S, Oldenburg J, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, De Santis M.

Ann Oncol. 2012 Jan;23(1):59-64. doi: 10.1093/annonc/mdr052. Epub 2011 Apr 2.

PMID:
21460378
47.

Drug delivery vehicles with improved encapsulation efficiency: taking advantage of specific drug-carrier interactions.

Kita K, Dittrich C.

Expert Opin Drug Deliv. 2011 Mar;8(3):329-42. doi: 10.1517/17425247.2011.553216. Epub 2011 Feb 16. Review.

PMID:
21323506
48.

Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.

Königsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, de Santis M, Zeillinger R, Hudec M, Dittrich C.

Acta Oncol. 2011 Jun;50(5):700-10. doi: 10.3109/0284186X.2010.549151. Epub 2011 Jan 24.

PMID:
21261508
49.

Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients.

Königsberg R, Pfeiler G, Kurzawa R, Hudec M, Zeillinger R, Dittrich C, Singer C.

Cancer Invest. 2011 Feb;29(2):180-6. doi: 10.3109/07357907.2010.543215.

PMID:
21261479
50.

Solid peptide nanoparticles--structural characterization and quantification of cargo encapsulation.

Dittrich C, Meier W.

Macromol Biosci. 2010 Dec 8;10(12):1406-15.

PMID:
21166104

Supplemental Content

Loading ...
Support Center